LATEST UPDATES » Vol 24, No. 07, July 2020 – Mitigating the Impact of COVID-19: How is Food Security Threatened?       » COVID-19 vaccine Reaches Phase I Clinical Trial       » Mathematical Model to Define Eruptive Stages of Young Volcanic Rocks       » Artificial Intelligence to Tackle Agricultural Challenges       » Installation of Mobile X-Ray System at COVID-19 Screening Center in Korea       » World's First Spherical Artificial Eye      
Vol 22, No. 01, January 2018   |   Issue PDF view/purchase
Eisai's Aricept approved for additional indication of severe Alzheimer's disease in China
Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China.

Eisai Co., Ltd. announced that Aricept (donepezil hydrochloride) has been approved for the additional indication of severe Alzheimer's disease in China. Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China.

The approval of the additional indication was based on the results of a Phase III clinical study (Study 3391) in China. Study 339 was a multi-center, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of Aricept 10 mg per day in 313 Chinese patients with severe Alzheimer's disease. In this study, Aricept demonstrated a statistically significant improvement in total Severe Impairment Battery scores after 24 weeks compared to placebo, which was the primary endpoint of the study. In the study, the four most commonly observed adverse events in the Aricept arm were bradycardia, anorexia, QT interval prolongation, and dizziness.

In China, it has been estimated that approximately 6 million people suffer from Alzheimer's disease. Furthermore, with the progressive aging of the population, the number of patients with dementia is expected to greatly increase in the future.

With the approval of this indication covering severe Alzheimer's disease, Eisai strives to further contribute to increasing the quality of life of patients with Alzheimer's disease in China, and as the originator of Aricept, continues to make comprehensive contributions in dementia such as improving treatment and care, increasing public awareness of the disease and discovering new treatment methods.

news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Group
news Twist Bioscience and Proteona Join Hands to Protect Immunocompromised Patients from COVID-19 Infection
news Innovation in Healthcare: IOT-Enabled Tele-Ventilators to Fight Against the COVID-19 Pandemic
news Proteona leads international consortium to develop SARS-CoV-2 neutralizing antibody to help vulnerable immunocompromised individuals

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy